<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27805" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Promethazine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Southard</surname>
            <given-names>Brittin T.</given-names>
          </name>
          <aff>Brooke Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Khalili</surname>
            <given-names>Yasir</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brittin Southard declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasir Al Khalili declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27805.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Promethazine is a medication used to manage and treat allergic conditions, nausea and vomiting, motion sickness, and sedation. Promethazine also has off-label uses for nausea and vomiting in pregnancy. Promethazine is a phenothiazine derivative with antidopaminergic, antihistamine, and anticholinergic properties. Promethazine is a phenothiazine derivative with antidopaminergic, antihistamine, and anticholinergic properties. Other phenothiazine derivatives include prochlorperazine and chlorpromazine. Promethazine works as a direct antagonist at the mesolimbic dopamine receptors and alpha-adrenergic receptors in the brain. Promethazine exhibits its antihistamine effects as an H1-receptor blocker. This activity reviews the FDA approved-indications, mechanism of action, administration, dosing, adverse drug reactions, contraindications, warning, precautions, monitoring, and toxicity of promethazine. In addition, this activity will highlight the pertinent interprofessional roles of the interprofessional team during the use of promethazine n the treatment of patients with allergic conditions, nausea and vomiting, motion sickness, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for promethazine use, such as allergic conditions, nausea, vomiting, and motion sickness.</p></list-item><list-item><p>Screen patients for contraindications, potential drug interactions, and risks associated with promethazine therapy.</p></list-item><list-item><p>Assess patients' response to promethazine therapy and monitor for adverse effects and treatment efficacy.</p></list-item><list-item><p>Communicate effectively with patients about the benefits, risks, and potential side effects of promethazine therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27805&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27805">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27805.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic conditions: Promethazine is a first-generation antihistamine, and thus it is indicated for various allergic conditions, including seasonal allergic rhinitis and&#x000a0;allergic conjunctivitis, uncomplicated skin manifestations of urticaria, and angioedema.<xref ref-type="bibr" rid="article-27805.r1">[1]</xref><xref ref-type="bibr" rid="article-27805.r2">[2]</xref> Promethazine is also indicated as adjunctive therapy to epinephrine for anaphylactic reactions.<xref ref-type="bibr" rid="article-27805.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Nausea and vomiting: Phenothiazines such as promethazine have substantial antiemetic activity. Clinicians use promethazine to control nausea and vomiting associated with anesthesia or chemotherapy.<xref ref-type="bibr" rid="article-27805.r4">[4]</xref><xref ref-type="bibr" rid="article-27805.r5">[5]</xref> Promethazine is commonly used postoperatively as an antiemetic. The antiemetic activity increases with increased dosing; however, side effects also increase, often limiting maximal dosing.<xref ref-type="bibr" rid="article-27805.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Motion sickness: Promethazine can serve as prophylactic therapy for motion sickness; it is most effective when given 30 minutes to 1 hour before the triggering event.<xref ref-type="bibr" rid="article-27805.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Sedation: Promethazine can be used as adjunctive therapy with other analgesics to provide preoperative, postoperative, or obstetric sedation.<xref ref-type="bibr" rid="article-27805.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-label Usage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea and vomiting associated with pregnancy: According to the American College of Obstetrics, promethazine is useful in nausea and vomiting during pregnancy when preferred agents do not provide symptomatic relief.<xref ref-type="bibr" rid="article-27805.r9">[9]</xref>&#x000a0;A double-blinded randomized controlled trial of intravenous promethazine versus metoclopramide in women with hyperemesis gravidarum found similar efficacy between the two drugs in controlling nausea and vomiting at 24 hours but found increased&#x000a0;adverse effects in the promethazine group, such as dry mouth, drowsiness, dizziness, and dystonia.<xref ref-type="bibr" rid="article-27805.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27805.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Promethazine is a phenothiazine derivative with antidopaminergic, antihistamine, and anticholinergic properties. Other phenothiazine derivatives include prochlorperazine and chlorpromazine. Promethazine works as a direct antagonist at the mesolimbic dopamine receptors and alpha-adrenergic receptors in the brain. Promethazine exhibits its antihistamine effects as an H1-receptor blocker.<xref ref-type="bibr" rid="article-27805.r11">[11]</xref><xref ref-type="bibr" rid="article-27805.r12">[12]</xref></p>
      </sec>
      <sec id="article-27805.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Promethazine has several routes of administration, including oral, rectal, intramuscular, and intravenous.&#x000a0;The tablets, solutions, and suppository dose is generally 12.5 mg to 50 mg.</p>
        <list list-type="bullet">
          <list-item>
            <p>Promethazine hydrochloride injection solution: 25 mg/mL; 50 mg/mL</p>
          </list-item>
          <list-item>
            <p>Promethazine hydrochloride oral solution: 6.25 mg/5 mL</p>
          </list-item>
          <list-item>
            <p>Promethazine hydrochloride suppository: 12.5 mg; 25 mg; 50 mg</p>
          </list-item>
          <list-item>
            <p>Promethazine hydrochloride oral syrup: 6.25 mg/5 mL</p>
          </list-item>
          <list-item>
            <p>Promethazine hydrochloride oral tablets: 12.5 mg, 25 mg, 50 mg</p>
          </list-item>
        </list>
        <p>Promethazine should be given with food, water, or milk to decrease gastrointestinal discomfort when administered orally.&#x000a0;The intramuscular injection must be into deep muscle tissue as the subcutaneous injection may damage tissue. Intravenous use should be performed with caution as severe tissue damage may also occur. Promethazine may be diluted before IV administration in selected patients to prevent promethazine-induced tissue necrosis.<xref ref-type="bibr" rid="article-27805.r13">[13]</xref><xref ref-type="bibr" rid="article-27805.r14">[14]</xref></p>
        <p>In pediatric patients, promethazine utilizes the same routes of administration as adults. However, dosing adjustments are necessary based on the weight of the patient and the indication. Using the lowest dose of efficacy is recommended.</p>
        <p>
<bold>Allergy</bold>
<bold>&#x000a0;</bold>
</p>
        <p>The normal recommended oral dose is 25 mg administered before bed; alternatively, a patient can be given 6.25 to 12.5 mg three times before meals and on retiring, as necessary. After initiation of the treatment, the dose should be adjusted to the minimum dose to relieve the symptoms adequately in children or adults.</p>
        <p>
<bold>Motion Sickness</bold>
</p>
        <p>The average recommended adult dose is 25 mg, taken twice daily. The initial dose needs to be taken one-half to one hour before travel and repeated every eight to twelve hours later if needed. On days following travel, 25 mg can be administered when up and repeated before the evening meal. Promethazine hydrochloride syrup, tablets, or rectal suppositories are administered at 12.5 to 25 mg twice daily for children.<xref ref-type="bibr" rid="article-27805.r7">[7]</xref></p>
        <p>
<bold>Nausea and Vomiting</bold>
</p>
        <p>Antiemetics are not recommended to treat vomiting of unknown etiology in children and adolescents. The average effective dose of promethazine for the active treatment of nausea and vomiting in children or adults is 25 mg. Patients who do not tolerate oral medication can be administered parenterally or rectally. Promethazine, 12.5 mg to 25 mg, may be repeated at&#x000a0;4 to 6-hour intervals. To treat nausea and vomiting in children, the usual recommended dose is 0.5 mg/pound (body weight). The dose should be based on the patient's age, body weight, and the severity of nausea/vomiting. During surgery and the postoperative period, the recommended dose is 25 mg administered at four to six-hour intervals for prophylaxis of nausea and vomiting.<xref ref-type="bibr" rid="article-27805.r10">[10]</xref></p>
        <p>
<bold>Sedation</bold>
<bold>&#x000a0;</bold>
</p>
        <p>Promethazine relieves apprehension, inducing a quiet sleep from which the person can be easily aroused. Administer 12.5 mg to 25 mg promethazine orally or rectally at bedtime to provide sedation in children. Adults usually need 25 mg to 50 mg before surgery to relieve apprehension and produce quiet sleep for nighttime, obstetrical, or presurgical sedation. Children need 0.5 mg promethazine/pound (body weight) as a preoperative medication combined with adequately reduced narcotic/barbiturate and the required amount of an atropine-like drug.</p>
        <p>The usual recommended adult dosage is 50 mg promethazine with an adequately reduced dose of narcotic/barbiturate and the appropriate dose of a belladonna alkaloid. Postoperative sedation and adjunctive use with analgesic medicines may be achieved by the 12.5 mg to 25 mg promethazine in children and 25 mg to 50 mg promethazine in adults.</p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Patients With Hepatic Impairment: </bold>No dose adjustment is provided in the manufacturer's labeling. Use with caution due to the risk of cholestatic jaundice.<xref ref-type="bibr" rid="article-27805.r15">[15]</xref></p>
        <p><bold>Patients With Renal Impairment: </bold>No dose adjustment is required in patients with renal impairment.</p>
        <p><bold>Pregnancy Considerations: </bold>Research has also identified phenothiazines as a potential cause of congenital malformations in one study, but other studies attest to their safety.<xref ref-type="bibr" rid="article-27805.r16">[16]</xref>&#x000a0;Promethazine is classified as a former FDA pregnancy category C by the FDA. Alternative therapies may be indicated before promethazine, considering the risks to the fetus and adverse effects on the mother.<xref ref-type="bibr" rid="article-27805.r17">[17]</xref></p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Short-term use of promethazine poses little risk to the breastfed infant due to the minimal excretion of phenothiazine derivatives. However, observe infants for excess sedation with repeated doses. Promethazine can reduce prolactin secretion but may interfere with lactation if given during labor before lactation is established. Consider risk-benefit evaluation before prescribing promethazine.<xref ref-type="bibr" rid="article-27805.r18">[18]</xref></p>
        <p><bold>Pediatric Patients: </bold>Promethazine is included in the KIDs List (Key Potentially&#x000a0;Inappropriate&#x000a0;Drugs in Pediatrics).<xref ref-type="bibr" rid="article-27805.r19">[19]</xref>&#x000a0;Promethazine has also been associated with sudden infant death syndrome.<xref ref-type="bibr" rid="article-27805.r20">[20]</xref></p>
        <p><bold>Older&#x000a0;Patients: </bold>Promethazine is included in American Geriatric Society&#x000a0;Beers Criteria as a potentially inappropriate medication for older adults due to anticholinergic adverse effects.<xref ref-type="bibr" rid="article-27805.r21">[21]</xref></p>
      </sec>
      <sec id="article-27805.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Promethazine has several potential adverse effects related to its mechanism of action. The most common side effects include sedation, confusion, and disorientation, which may impair physical and mental abilities. However, promethazine may paradoxically cause excitability, restlessness, or, rarely, seizures.</p>
        <p>Promethazine&#x02019;s anticholinergic properties may cause&#x000a0;adverse effects, including blurred vision, xerostomia, dry nasal passages, dilated pupils, constipation, and urinary retention.<xref ref-type="bibr" rid="article-27805.r20">[20]</xref></p>
        <p>Promethazine&#x02019;s antidopaminergic properties may result in extrapyramidal symptoms, including pseuodoparkinsonism, acute dystonia, akathisia, and tardive dyskinesia. Promethazine, therefore, may worsen symptoms in patients with Parkinson disease.<xref ref-type="bibr" rid="article-27805.r21">[21]</xref></p>
        <p>Less common adverse effects that prescribers should be aware of include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The neuroleptic malignant syndrome may also have associations with promethazine usage, which manifests as increased body temperature, confusion or altered mental status, sweating, autonomic instability, and &#x0201c;lead pipe&#x0201d; rigidity.</p>
          </list-item>
          <list-item>
            <p>Cardiovascular side effects include arrhythmias and hypotension.</p>
          </list-item>
          <list-item>
            <p>Reports also exist of liver damage and cholestatic jaundice with its use.</p>
          </list-item>
          <list-item>
            <p>Bone marrow suppression potentially results in agranulocytosis, thrombocytopenia, and leukopenia.</p>
          </list-item>
          <list-item>
            <p>Depression of the thermoregulatory mechanism results in hypothermia/hyperthermia.</p>
          </list-item>
        </list>
        <p>
<bold>Boxed Warnings</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In children less than two years old, reports exist of respiratory depression resulting in fatalities.<xref ref-type="bibr" rid="article-27805.r22">[22]</xref> For this reason, there is a US-boxed warning on the use of promethazine in children less than two years of age.<xref ref-type="bibr" rid="article-27805.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Promethazine may cause serious tissue injury on injection, including gangrene, regardless of the route of administration. This effect may occur due to extravasation, unintentional intra-arterial administration, and intraneuronal or perineuronal infiltration, manifesting as burning, pain, erythema, edema, severe spasms, phlebitis, thrombophlebitis, venous thrombosis, sensory loss, paralysis, and palsies.<xref ref-type="bibr" rid="article-27805.r13">[13]</xref><xref ref-type="bibr" rid="article-27805.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27805.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Promethazine contraindications include patients with hypersensitivity to the drug, any drug components, or other phenothiazines.&#x000a0;The drug is contraindicated in children under two years of age due to the risk of potentially fatal respiratory depression. Promethazine is contraindicated for subcutaneous or intra-arterial administration due to the risk of tissue damage. Contraindications also include comatose patients and patients with lower respiratory tract symptoms.<xref ref-type="bibr" rid="article-27805.r13">[13]</xref><xref ref-type="bibr" rid="article-27805.r19">[19]</xref></p>
        <p>
<bold>Precautions/Warnings</bold>
</p>
        <p><bold>Seizures:</bold> Promethazine should be used cautiously in patients with seizure disorders or in persons taking concomitant medications, which may also lower seizure threshold (ie, narcotics, local anesthetics, etc).</p>
        <p><bold>Bone-Marrow Depression</bold>: Promethazine should be used cautiously in patients with bone marrow depression (Leukopenia and agranulocytosis). The risk is higher when it is coadministered with other known marrow-toxic agents.</p>
        <p><bold>Neuroleptic Malignant Syndrome:</bold>&#x000a0;A potentially fatal NMS is reported in patients using promethazine alone or combined with other antipsychotic drugs. Clinical symptoms of NMS are hyperpyrexia, altered mental status, muscle rigidity, and autonomic instability (diaphoresis, irregular heartbeats or blood pressure, tachycardia, and cardiac dysrhythmias). The diagnostic evaluation of patients with NMS is complicated.&#x000a0;Clinicians must identify patients when the clinical presentation includes untreated or inadequately treated EPS and serious medical conditions (eg, pneumonia, systemic infection, etc).<xref ref-type="bibr" rid="article-27805.r23">[23]</xref></p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p><bold>Central-Nervous-System Depressants:</bold> Promethazine may intensify, increase, or prolong the sedative action of other CNS depressants, such as tricyclic antidepressants, sedatives/hypnotics, narcotics, narcotic analgesics, alcohol, general anesthetics, and tranquilizers; therefore, those medicines should be avoided or administered in a lower dosage to patients taking promethazine concomitantly.</p>
        <p>When promethazine is concomitantly administered, the dose of barbiturates should be reduced by at least 50% and narcotics by 25% to 50%. Dosage must be individualized according to the patient's clinical presentation. High amounts of promethazine relative to narcotics may lead to motor hyperactivity and restlessness in the patient with pain, and these symptoms normally disappear with adequate pain management.</p>
        <p><bold>Anticholinergics:&#x000a0;</bold>Concomitant use of other medicines with anticholinergic properties&#x000a0;requires caution.</p>
        <p><bold>Monoamine Oxidase Inhibitors (MAOI):</bold>&#x000a0;Concomitant use can result in drug interactions, including an increased incidence of EPS.</p>
        <p><bold>Drug/Laboratory Test Interactions: </bold>Some laboratory tests may be altered in patients receiving promethazine therapy. Diagnostic pregnancy test results based on HCG and anti-HCG immunological reactions could result in false-positive or false-negative interpretations. Also, a&#x000a0;glucose tolerance test may report falsely elevated blood glucose levels in patients receiving promethazine.&#x000a0;False-positive urine amphetamine results&#x000a0;can occur&#x000a0;due to&#x000a0;promethazine.<xref ref-type="bibr" rid="article-27805.r24">[24]</xref><xref ref-type="bibr" rid="article-27805.r25">[25]</xref></p>
      </sec>
      <sec id="article-27805.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Due to promethazine&#x02019;s side effect profile, any medical personnel who administers the drug should be aware of potential side effects. Healthcare providers must monitor patients for burning or pain at the injection site, phlebitis, blistering, or swelling, which may indicate tissue damage.<xref ref-type="bibr" rid="article-27805.r14">[14]</xref></p>
        <p>Extrapyramidal and anticholinergic side effects also require monitoring, and providers should be notified immediately if they appear. Promethazine is also a CNS depressant, so safety measures such as side rail up and call light within reach should be in place.</p>
      </sec>
      <sec id="article-27805.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The main feature of promethazine toxicity is CNS depression, tachycardia, respiratory depression, and delirium. Supportive care and monitoring are the treatment for most overdoses, as no known antidote exists. Significant overdoses with profoundly depressed mental status or coma may require airway support, hemodynamic monitoring, and a higher level of care. Some studies have shown that early administration of charcoal within&#x000a0;two hours may be beneficial. However, the evidence is still lacking, and further studies are necessary.<xref ref-type="bibr" rid="article-27805.r11">[11]</xref>&#x000a0;Because promethazine can reverse epinephrine&#x02019;s vasopressor effect, epinephrine should not be used for hypotension associated with promethazine overdose.</p>
        <p>
<bold>Management of NMS</bold>
</p>
        <p>Immediate discontinuation of promethazine, antipsychotic drugs, and other drugs is essential to concurrent treatment. Intensive symptomatic treatment and medical monitoring are required. Provide therapy for concomitant serious medical problems where specific treatments are available. There are no general recommendations or specific pharmacological treatment protocols for uncomplicated NMS.</p>
        <p>However, as reoccurrences of NMS have been reported with phenothiazines class medicines, the reintroduction of promethazine should be carefully done. Facilitate heat dissipation and administer IV fluids for dehydration. Administer IV&#x000a0;benzodiazepines&#x000a0;for seizures and agitation. Consider bromocriptine and dantrolene(off-label) in consultation with a neurologist and critical care specialist.<xref ref-type="bibr" rid="article-27805.r26">[26]</xref><xref ref-type="bibr" rid="article-27805.r27">[27]</xref></p>
      </sec>
      <sec id="article-27805.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Promethazine is a relatively safe medication that is very useful in treating several conditions, such as nausea/vomiting, allergic disorders, prevention of motion sickness, and pre/post-operative or obstetric&#x000a0;sedation. However, drug prescribers&#x000a0;should be aware of the potential side effects and contraindications. In addition, providers must be mindful of the two boxed warnings associated, which include the potential to cause severe tissue damage with IM/IV injection and potentially fatal respiratory depression in children under two years of age.</p>
        <p>Therefore, close interprofessional coordination between physicians, advanced practice practitioners, specialists, nursing staff, pharmacists, and other healthcare workers is necessary to improve patient outcomes and decrease promethazine's adverse effects. Pharmacists can reconcile the patient's medication profile and report to the nurse or prescribing clinician if any interactions exist. Nurses will often be the first to see the patient and monitor for apparent adverse effects, either reporting to the prescriber or checking with the pharmacist regarding the adverse event profile of promethazine. Nursing is also in charge of IV administration to have first-line exposure to issues such as extravasation and can inform the clinician. The interprofessional healthcare team must collaborate, each discipline bringing expertise to support shared decision-making, leading to positive patient outcomes.</p>
      </sec>
      <sec id="article-27805.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27805&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27805">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27805/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27805">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27805.s11">
        <title>References</title>
        <ref id="article-27805.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Blessing-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Portnoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tilles</surname>
                <given-names>SA</given-names>
              </name>
              <collab>Joint Task Force on Practice</collab>
              <collab>American Academy of Allergy</collab>
              <collab>Asthma &#x00026; Immunology</collab>
              <collab>American College of Allergy</collab>
              <collab>Asthma and Immunology</collab>
              <collab>Joint Council of Allergy, Asthma and Immunology</collab>
            </person-group>
            <article-title>The diagnosis and management of rhinitis: an updated practice parameter.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>122</volume>
            <issue>2 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-84</page-range>
            <pub-id pub-id-type="pmid">18662584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Leech</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Till</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Nasser</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>AT</given-names>
              </name>
              <collab>British Society for Allergy and Clinical Immunology</collab>
            </person-group>
            <article-title>BSACI guideline for the management of chronic urticaria and angioedema.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>547</fpage>
            <page-range>547-65</page-range>
            <pub-id pub-id-type="pmid">25711134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuberbier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aberer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Asero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bindslev-Jensen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brzoza</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Ensina</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gim&#x000e9;nez-Arnau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godse</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grattan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hebert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hide</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kapp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdul Latiff</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Mathelier-Fusade</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Borges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmid-Grendelmeier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Simons</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Staubach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sussman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Toubi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vena</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Wedi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
              <collab>European Academy of Allergy and Clinical Immunology</collab>
              <collab>Global Allergy and Asthma European Network</collab>
              <collab>European Dermatology Forum</collab>
              <collab>World Allergy Organization</collab>
            </person-group>
            <article-title>The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.</article-title>
            <source>Allergy</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>868</fpage>
            <page-range>868-87</page-range>
            <pub-id pub-id-type="pmid">24785199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grunberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hesketh</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Control of chemotherapy-induced emesis.</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Dec</month>
            <day>09</day>
            <volume>329</volume>
            <issue>24</issue>
            <fpage>1790</fpage>
            <page-range>1790-6</page-range>
            <pub-id pub-id-type="pmid">8232489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tortorice</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Management of chemotherapy-induced nausea and vomiting.</article-title>
            <source>Pharmacotherapy</source>
            <year>1990</year>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-45</page-range>
            <pub-id pub-id-type="pmid">2190193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Apfel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Kovac</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Myles</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Samsa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sessler</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Temo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tram&#x000e8;r</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Vander Kolk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Watcha</surname>
                <given-names>M</given-names>
              </name>
              <collab>Society for Ambulatory Anesthesia</collab>
            </person-group>
            <article-title>Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting.</article-title>
            <source>Anesth Analg</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>1615</fpage>
            <page-range>1615-28, table of contents</page-range>
            <pub-id pub-id-type="pmid">18042859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shupak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Motion sickness: advances in pathogenesis, prediction, prevention, and treatment.</article-title>
            <source>Aviat Space Environ Med</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>77</volume>
            <issue>12</issue>
            <fpage>1213</fpage>
            <page-range>1213-23</page-range>
            <pub-id pub-id-type="pmid">17183916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>POTTS</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>ULLERY</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Maternal and fetal effects of obstetric analgesia. Intravenous use of promethazine and meperidine.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1961</year>
            <month>Jun</month>
            <volume>81</volume>
            <fpage>1253</fpage>
            <page-range>1253-9</page-range>
            <pub-id pub-id-type="pmid">13737524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>e15</fpage>
            <page-range>e15-e30</page-range>
            <pub-id pub-id-type="pmid">29266076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Khine</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Vallikkannu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Omar</surname>
                <given-names>SZ</given-names>
              </name>
            </person-group>
            <article-title>Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial.</article-title>
            <source>Obstet Gynecol</source>
            <year>2010</year>
            <month>May</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>975</fpage>
            <page-range>975-981</page-range>
            <pub-id pub-id-type="pmid">20410771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Duffull</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Promethazine overdose: clinical effects, predicting delirium and the effect of charcoal.</article-title>
            <source>QJM</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-31</page-range>
            <pub-id pub-id-type="pmid">19042969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamelin</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view.</article-title>
            <source>Curr Drug Metab</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-29</page-range>
            <pub-id pub-id-type="pmid">12678691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reynolds</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>MacLaren</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Kiser</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Management of extravasation injuries: a focused evaluation of noncytotoxic medications.</article-title>
            <source>Pharmacotherapy</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>617</fpage>
            <page-range>617-32</page-range>
            <pub-id pub-id-type="pmid">24420913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hurst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Innovative solutions in critical care units: extravasation guidelines.</article-title>
            <source>Dimens Crit Care Nurs</source>
            <year>2004</year>
            <season>May-Jun</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>125</fpage>
            <page-range>125-8</page-range>
            <pub-id pub-id-type="pmid">15192356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Dopamine receptor antagonists.</article-title>
            <source>Ann Palliat Med</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-42</page-range>
            <pub-id pub-id-type="pmid">25841474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e1;rtfai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kocsis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Puh&#x000f3;</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Czeizel</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>A population-based case-control teratologic study of promethazine use during pregnancy.</article-title>
            <source>Reprod Toxicol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>276</fpage>
            <page-range>276-85</page-range>
            <pub-id pub-id-type="pmid">18272326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rumeau-Rouquette</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goujard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Possible teratogenic effect of phenothiazines in human beings.</article-title>
            <source>Teratology</source>
            <year>1977</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-64</page-range>
            <pub-id pub-id-type="pmid">841482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Promethazine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starke</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Boxed warning added to promethazine labeling for pediatric use.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Jun</month>
            <day>23</day>
            <volume>352</volume>
            <issue>25</issue>
            <fpage>2653</fpage>
            <pub-id pub-id-type="pmid">15972879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cantisani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grieco</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Paolino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Faina</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calvieri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Topical promethazine side effects: our experience and review of the literature.</article-title>
            <source>Biomed Res Int</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>151509</fpage>
            <pub-id pub-id-type="pmid">24350243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control (CDC)</collab>
            <article-title>Neonatal deaths associated with use of benzyl alcohol--United States.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>1982</year>
            <month>Jun</month>
            <day>11</day>
            <volume>31</volume>
            <issue>22</issue>
            <fpage>290</fpage>
            <page-range>290-1</page-range>
            <pub-id pub-id-type="pmid">6810084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waldorf</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>AANA journal course. Update for nurse anesthetists. Neuroleptic malignant syndrome.</article-title>
            <source>AANA J</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>389</fpage>
            <page-range>389-94</page-range>
            <pub-id pub-id-type="pmid">14625976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melanson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lee-Lewandrowski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Griggs</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>130</volume>
            <issue>12</issue>
            <fpage>1834</fpage>
            <page-range>1834-8</page-range>
            <pub-id pub-id-type="pmid">17149959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brahm</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Yeager</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Commonly prescribed medications and potential false-positive urine drug screens.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2010</year>
            <month>Aug</month>
            <day>15</day>
            <volume>67</volume>
            <issue>16</issue>
            <fpage>1344</fpage>
            <page-range>1344-50</page-range>
            <pub-id pub-id-type="pmid">20689123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ngo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guerrero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanum</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burgett-Moreno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fenati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neeki</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene.</article-title>
            <source>Clin Pract Cases Emerg Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-23</page-range>
            <pub-id pub-id-type="pmid">30775657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27805.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strawn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Keck</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Caroff</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome.</article-title>
            <source>Am J Psychiatry</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>164</volume>
            <issue>6</issue>
            <fpage>870</fpage>
            <page-range>870-6</page-range>
            <pub-id pub-id-type="pmid">17541044</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
